Matica Biotechnology, Inc. (Matica Bio), recognized as a leading contract development and manufacturing organization (CDMO) specializing in viral vector production, has announced a strategic partnership with Cirsium Biosciences, a biotechnology firm pioneering plant-based AAV (adeno-associated virus) technology. This non-exclusive collaboration reflects Cirsium's hybrid hub-and-spoke manufacturing model, which integrates internal plant-based AAV production with downstream partners to optimize flexibility, scalability, and distribution. By entering this agreement, Matica Bio is positioning itself as an early adopter, offering analytical and downstream support that aligns with Cirsium's innovative technology. The current challenges in AAV manufacturing, particularly regarding cost and efficiency, pose significant barriers to the development and accessibility of gene therapies. Solutions that streamline production cycles and enhance scalability are critical for the industry's ongoing growth. Together, Matica Bio and Cirsium are committed to facilitating more efficient manufacturing processes, ultimately allowing for quicker and wider patient access.

"Partnering with Cirsium means working alongside a company committed to advancing innovation in gene therapy," said Paul Kim, CEO of Matica Bio. "We are proud to be an early partner in this decentralized model. Their innovative technology aligns seamlessly with our extensive capabilities in viral vector development and the manufacturing of clinical products. Together, we're working to shape the future of next-generation treatments and expand availability to more patients." Dr. Daniel Gibbs, CEO of Cirsium, added, "Our hub-and-spoke model allows us to partner with leading organizations like Matica Bio to expand AAV manufacturing flexibility and scalability. This collaboration reflects our mission to pursue more efficient approaches to gene therapy manufacturing."